Innovation in the Post-TRIPs Regime in Indian Pharmaceutical Firms: Implications for Pharmaceutical Innovation Model by Chaturvedi, Kalpana & Chataway, Joanna
Innovation in the Post-TRIPs Regime in Indian Pharmaceutical Firms: 
Implications for Pharmaceutical Innovation Model 
 
Kalpana Chaturvedi and Joanna Chataway 
 
1. Introduction 
Innovation is considered to be one of the most important factors in economic competition 
(Pohlmann, 2005). But innovation does not happen merely by chance. The established 
literature provides vivid description of technological trajectories, paradigms, innovation 
paths, and long waves of innovation models (Schumpeter 1947, Nelson and Winter 1977, 
Dosi 1982 and Rothwell 1992). This literature views innovation as an evolutionary 
process and asserts that accumulation of skills, experience and technical know-how, 
whether at the level of firms or of countries, accumulates over time. This means that 
technology is not something which firms simply choose and buy-in from outside. On the 
contrary, it is rooted in a specific set of change generating resources (context) or 
absorptive and innovative capabilities firmly rooted within the structure of technology-
oriented firms. In addition, temporal and contextual f ctors are important in 
understanding the shaping of an industry within which the critical actors (mainly firms 
and government) are embedded and perform (Freeman et l 1988). For example factors 
such as: social requirements, economic status, infrastructure, and policies, may or may 
not be conducive for innovation in a particular sector or country.  
 
Policies can play a major role in stimulating and supporting the innovation process, 
notably by shaping the parameters within which choies are made and by agenda setting 
that targets specific actions for immediate attention. No better example can be cited here 
than the evolution of Indian pharmaceutical industry under the Indian Patents Act, 1970.  
This act shaped the reverse engineered based strategies of leading pharmaceutical firms.  
 
In the 1970s there was a vast difference in the technology paradigms and trajectories 
followed by the firms in India and in the developed countries and the policy influence of 
the Indian state was evident. Much has changed since the 1990s with the opening of the 
Indian economy and later with the signing of the TRIPs agreement. Product patents are 
not new to India, having been established in the early 20th century. However, the context 
has changed. The major distinctive features of the current era are: a) degree of 
globalisation; and  b) dispersed innovative capacities within the global pharmaceutical 
industry. Policy changes both at the national and international level such as liberalisation, 
globalisation and patent harmonisation along with other forces (market and knowledge) 
have influenced innovation strategies of Indian and multinational firms alike. The 
implications of these new characteristics on innovati n models in the pharmaceutical 
industry is the focus of this paper. The challenge to firms in this era is to manage the 
tension between integration of knowledge from different sources and the fragmentation 
which occurs as a result of needing to outsource rathe  than fully integrate. The paper 
links advances in innovation theory with practice (firm level dynamics) by tracing the 
changing context of innovation and technological developments in Indian pharmaceutical 
firms in the recent past. 
 
Analysis of recent literature about constantly changing innovation dynamics, policy and 
firm level strategies in this paper provides deep insights into why and how the process 
has changed over time. Evolutionary economists emphasize the cumulative and 
dependent nature of technical and organisational chnge within firms. The particularities 
of the way different firms incorporate new technology and new processes needs to be 
understood in the context of their previous trajectories and their capacity to absorb new 
knowledge (Cohen and Levinthal 1990). The notion of path dependence has been 
deployed in the economic history and historical sociol gy literatures to explain sequences 
of events related mainly to technological and institutional evolution (David 1994). In this 
paper the notion is adopted to subdivide sequences of vents and self-reinforcing reactive 
strategies at the level of firms. The findings of this paper illustrate the distinctive 
competencies and capabilities created by leading Indian pharmaceutical firms during 
different policy regimes in the past and the reconfiguration of their existing competencies 
for survival and success in the new innovation-led business environment.  
 
2. Structure of the Paper  
The principle objective of this paper is to analyse th  interaction between public policy 
and firm level strategies; and their resultant and cumulative impact on drug innovation 
models in the Indian pharmaceutical industry.  Section 3 presents the research context 
and the theoretical framework used in this paper. This section also describes the 
methodology of the study and rationale behind our research design. Section 4 maps the 
technology and policy co-evolution in the Indian pharmaceutical industry since 
independence. Providing the necessary historical background, this section explains 
capacities and capabilities created within the India pharmaceutical industry in the process 
patent regime and shows how changes in policy regims have influenced technological 
choices and trajectories of Indian firms over time. S ction 5 identifies the key drivers for 
research and innovation in the next phase of development for the Indian pharmaceutical 
industry. Focusing on leading Indian firms, this section investigates their strategies to 
augment resources (particularly knowledge and skillet) prerequisite for drug discovery 
and development research in the post-TRIPs regime.  Section 6 discusses the 
transformation of Indian firms as they move from process engineering (working at the 
lower end) to drug discovery (higher end of pharmaceuti al value chain) and assesses the 
on-going and perspective changes in order to ascertain the direction it might take in the 
future. The paper concludes with a few final thoughts on the emerging drug innovation 
models in section 7.  
 
3.  Research Methodology and Theoretical Framework  
3.1 Research Methodology 
A review of firm level case studies in other developing countries like China, Korea and 
Taiwan (Kim 1997, Lee 2000) suggests that the creativ  destruction of existing 
competencies (process innovation in this case) and adoption of new practices (product 
innovation) is not an easy task and definitely not a ne-step-straightforward process. The 
move has to be gradual and needs to be addressed strategically rather than purely 
technically. Building further upon this framework, the present paper analyzes the gradual 
reorientation of Indian firms towards innovation-based R&D. Focusing at firm level, the 
paper looks at research and innovation strategies that are being devised by the top Indian 
firms to attain leadership in the domestic market and carve a niche for themselves in the 
international market in the post-TRIPs regime. Investigation of these issues in Indian 
pharmaceutical firms requires detailed information on the firm(s)’ history, R&D base, 
technical capabilities and its own technology policy and strategy. Multiple case studies 
are used in order to better understand how Indian firms are dealing with the changing 
policy, knowledge and markets emerging in the post-2005 scenario. Approaches to 
innovation in the post liberalization and TRIPs eraa e identified and analysed for their 
implications for policy-makers, firms and finally for innovation theory. Cases are chosen 
on the basis of degree of innovativeness in firms. The focus is on leading Indian firms. 
The multiple case study method allows replication lgic with each study confirming or 
disconfirming inferences from previous ones thereby permitting induction of more 
reliable strategies.  
 
Changes at the micro level are supplemented by macro nalysis. Existing literature has 
been used to analyse the causes and effects of the legal and policy changes in the last few 
decades on the growth and evolution of this industry. Literature has been sourced from 
the annual reports of the Ministry of Science and Technology, the Ministry of Commerce 
and Industry, Parliamentary reports and reports published by Individual organizations and 
authors (Ayyangar 1959, NCAER 1984, Watal 2000, Zaveri 2002) and discussions with 
industry experts. In addition, industry journals, trade journals, and industry associations’ 
publications are also referred to.  
 
3.2 Theoretical Framework 
The theoretical framework for this research is based upon the literature of co-evolution of 
policy and technology, strategic knowledge/innovation management and changing 
dynamics of innovation process. Focusing on the rolof ‘firms’ in ‘making’ policy work 
within a given context, this research examines how p licy analysis can be used not only 
to analyze the policy process, but also to better think about research, innovation and 
business strategies at firm level. 
  
Strong links between firms, policy and innovation in this particular sector have already 
been established in the literature (Forbes and Wield 2002, Chaudhuri 2004, Maskus 
2003). Many researchers have looked from different angles at how environmental factors 
such as policy, knowledge and market dynamics can affect firm level strategies 
(Chaturvedi and Chataway 2006, Halemane 2003, Madanmohan and Krishnan 2003, Fink 
2001). Building further upon this work, the present paper synthesizes contributions from 
three major areas, that is: the notion of technology innovation as an evolutionary and 
dynamic concept; the notion of firms being based on dynamic capabilities and 
competencies; and the notion that both endogenous and exogenous factors affect 
technological trajectories and innovation process at all levels (figure 1). The concepts and 
theories embedded in figure 1 such as: policy framework acting as a barrier/facilitator to 
innovation; organizational mechanisms such as strategic alliances and partnerships to 
bridge knowledge and innovation gaps; and strategies to mitigate cost, time and risk 
factor inherent in drug innovation (the core of thefigure) are utilized while examining the 
real life phenomena (practice at firms level) in this paper. 
 
4. Innovation: Policy and technology Interactions 
Dosi’s definition of technology paradigms and trajectories demonstrate that trajectories 
can be shaped along the economic and technological trade-offs defined by a paradigm. In 
this connection policy and development literature suggests that changes at the policy 
level account in a major way in which technologically dynamic firms and industries 
emerge and operate in both developing and developed countries (Lall 2003, Maskus 
2001, Correa 2000). Schumpeter (1947) with his ‘gales of creative destruction’ gave a 
vivid description of the dynamism of innovation and its effects on industrial and world 
economy. Many authors further contributed to this theory notably Rosenberg (1969), 
Nelson and Winter (1977), Dosi (1982), and Freeman and Prez (1988).  A number of 
studies have recently looked at the knowledge related policy changes in economic, social 
and technological development of the developing countries. Lanjouw and Cockburn 
(2001), Pradhan (2003), and Lalitha (2003) have studied the impact of the introduction of 
pharmaceutical product patents in India. This litera u e strongly suggests that the 
technological growth and development of a country are greatly influenced by the policies 
that help generate, absorb, diffuse and utilize technological innovations from elsewhere 
and innovate upon it. Working along the same lines the following section examines the 
role of policy interventions in promoting local ‘technology-generating efforts’ and 
‘production enterprises’ in the Indian pharmaceutical ndustry.          
 
4.1 Historical Perspective and Profile of the Indian Pharmaceutical Industry 
The history of the Indian pharmaceutical sector has been discussed in our previous papers 
in detail (Chaturvedi and Chataway 2006). The essential features of this history involve 
the progression from a production and innovation model based on reverse engineering 
since the 1970s Patents Act to a research-intensive model evolving from the mid 1990s 
after the signing of the TRIPs agreement.  
 
Before 1970, patent protection served to encourage foreign inventors and foreign R&D 
under the patents and Design Act, 1911 that India inherited from colonial periods,. MNCs 
patented their inventions in India, but did not produce locally, using the patents to 
establish protected foreign market in the country (A yangar Report 1959, p12). This not 
only denied the spillovers of technologies developed by MNCs to the local innovation 
system, but it also did not help developing local technological capabilities. The need for a 
system that encouraged technology acquisition, transfer, development, diffusion and 
incremental innovation was obvious. Patent law was used as a tool to establish a more 
productive innovation system in India; to counteract monopoly abuses by foreign 
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The Patents Act, 1970, represented a significant change in the legal and technological 
regime and had an enormous impact on the technological evolution of pharmaceutical 
industry in India. The 1970s Patents Act propelled Indian firms on a reverse engineering 
path and spurred the growth of a highly inward looking pharmaceutical firms focusing on 
the domestic market. The process patent regime allowed the domestic firms to undertake 
alternative process development. The domestic firms ma tered over the process chemistry 
and operational efficiencies to achieve high yield and productivity (Table 1). The 
‘imitative’ follower trajectory differs greatly from the technological trajectories followed 
by the firms in the US and Europe focusing on research nd new drug discovery. Many 
Indian firms, even though insignificant in size, were able to produce essential drugs like 
antibiotics at very economical prices. Price sensitive Indian consumers preferred local 
brands over the exorbitantly priced western brands.  
 
Table 1 
Production of Bulk Drugs and Formulations in India 
Value (in Rs. Crores) Year 
Bulk drugs Formulations Total 
1975-76 130 560 690 
1980-81 240 1,240 1,440 
1990-91 730 3,840 4,570 
1994-95 1,518 7,935 9,453 
1998-99 3,148 13,878 17,026 
Source: Department of Chemicals and Fertilizers, Various Annual Reports. 
 
The dynamics between local and western MNCs changed drastically from 1970s to 
1990s. The overall policy, technology and market enviro ment lowered the entry barriers 
and encouraged a large number of smaller enterprises to nter the market and compete 
with the MNCs in the domestic market. This resulted in disinvestment by MNCs that 
decided to exit the market. The market shares changed tremendously, bearing witness to 
the downfall of the western multinationals from the mid 1970s (Table 2). By the mid 
1990s the dominance and monopoly of MNCs was completely wiped out by the local 
firms.   
  
Table 2 
Changes in the Structural Composition of the Indian Pharmaceutical Indutry 
Nature of Firm 1970 1982 1993 
Western Multinationals 80 50 39 
Indian Public Sector 10  2  1 
Indian Private Sector 10 48 60 
Source: Redwood, 1994. 
 
The policy environment during 1980s provided an opportunity to learn while doing by 
eliminating fear of competition from more established and technologically advanced 
MNCs (Felker 1997). The technology progress during this period was mainly driven by 
‘technology-followers’ approach and ‘low-cost innovations and products’ goal. From an 
Indian perspective, lack of intellectual property rights laid the foundation for a strong 
domestic industry in the initial formative years and later gradual liberalization in 1990s 
enhanced competition and concern for quality and inovation.  
 
The fresh lease of reforms (liberalization) added pace to technological advancement. 
Much new technology was still imported but some leading firms started investing more in 
in-house R&D as a move to build a proprietary technological base (case-studies). “There 
were even more successful attempts to produce products better tailored than MNC drugs 
for the Indian market” (Smith 2000, p14). Driven by the large global generic markets of 
the developed world, Indian firms gradually created capability for generics R&D. 
Through the late 1980s and early 1990s, Indian firms grew increasingly sophisticated in 
their management and their strategy, focusing on backw rd integration, fragmentation 
and enhancing plant capacities. The reforms not only e abled the emergence of a 
competitive domestic industry but also set the foundation for generic drug production for 
international markets. 
 
After more than a decade of liberalization the macro-review of technological changes in 
India does not show any dramatic changes but the level of the individual firm (micro-
view) points to a more radical change in basic technology as well as in managing 
advanced technology. Many pharmaceutical firms likeCipla, Alembic, Cadila, Torrent 
and Lupin improved their manufacturing efficiency and established large production 
facilities. Sun, Zydus, Dabur, Ranbaxy and Wockhardt restructured and shifted their 
technology focus, product basket and market focus. Ranbaxy, Dr. Reddy’s, Sun, Lupin, 
Torrent and Wockhardt substantially increased their in-house R&D investments and 
implemented new approaches to drug/product development. Most technological changes 
were driven by competition in the liberalized market. Changes were not entirely due to 
liberalization; some ambitious and visionary firms had started taking technological 
initiatives even before liberalization nonetheless, liberalization did set the pace.  
 
Overall, competition with foreign firms and foreign products in the domestic market, 
exposure to the global markets, and realisation of future regulatory changes provided 
much needed innovative orientation to the imitative research in the early 1990s and 
tremendous boost to the production range and capacities. The number of brands in the 
domestic market with varying levels of credibility, vintages and therapeutic effectiveness, 
are over 6,500 in 77 therapeutic segments. The investments which stood at Rs. 2250 
million in 1973, rose to Rs. 6000 million by 1982, which further increased to Rs. 18400 
and Rs. 45000 million in 1997-98 and 2002-2003 (Nauriy l 2006). The average growth in 
the last few years has been about 12% (Ganguli 2003). Table 3 summarizes the growth 









Indian Pharmaceutical Industry: Growth Indicators ( in Rs. Million) 
Particulars 1965-66 1980-81 1997-98 1999-00 2002-01 2002-
03 
Capital Investment   1,400     5,000  18,400  25,000  29,000  45,000 
Production   1,680    14,400 146,910 197,370 228,870 392,547 
Formulation   1,500 12,000 120,680 159,600 183,540 238,659 
Bulk drugs      180     2,400 26,230 37,770 45,330  63,908 
Export     30.5        464 53,530 72,300 87,340 128,260 
Import        82      1125 28,680 16,160 29,800   28,650 
R&D Expenditure        30     147.5 2,200   3,200   3,700     6,600 
Source: Nauriyal, 2006 
 
5. New Patent Regime (TRIPs) and Challenges Ahead 
TRIPs marked the turning point of India’s policy regime towards the world. The 1970s 
Patents Act that facilitated the extraordinary growth of the domestic industry has been 
totally reversed with the signing of the TRIPs agreem nt in 1995. The TRIPs agreement 
requires WTO members to include ‘recognition of product patents for pharmaceuticals 
with 20 year terms’ in their domestic patent laws. Besides, importation of patented 
products once again satisfies the ‘working’ requirement of a patent (Pharma Policy 
2002). TRIPs has challenged both the government and local firms in many ways. At the 
national level, these challenges demand new initiatives beyond those enumerated in the 
Drug Policy 1985 (modified in 1994), so that policy inputs are directed more towards 
promoting accelerated growth of the industry and towards making it more internationally 
competitive. The Drug Policy 2002 has been framed against this backdrop. At firm level 
enhanced R&D focus is unarguable. The broadening of the IPR regime shifts the 
incentives for innovation creation from the second i novator to the first innovator 
(Ramani et al 2005). As a consequence major changes have occurred at the industry and 
firm level during the transition period (1995-2005). The key observations and our 
research findings are summarized below.  
 
5.1 Innovation Strategies in the Post-TRIPs Regime  
As is evident from our discussions in section 4, the knowledge base and capabilities of 
Indian pharmaceutical industry is firmly rooted in reverse engineering based R&D. Core-
competencies at the firm level created in the past however, vary from one to another firm 
and each firm has therefore devised a different strategy for itself in the post-TRIPs 
regime. Firms like Ranbaxy,      Dr. Reddy’s, Dabur, Sun, Wockhardt, and Torrent are 
seriously pursuing new drug discovery programs now. Our research suggests that these 
are the firms, generally, that have invested more in the R content of R&D and have 
gradually moved away from reverse engineering. Other firms like Cipla, Lupin, Cadila 
and NPIL have invested more in the D content and have strengthened their infrastructure 
and financial position through process efficiencies, economies of scale and large product 
baskets rather than research. These firms are of the opinion that technology needs to be 
fostered gradually and hence are taking a slightly different route to drug discovery. 
Within these two very broad categories there is further differentiation. Nonetheless R&D 
does seem to be judged as essential in the long term by all firms.  State of the art R&D 
facilities equipped with sophisticated instruments, equipments and skills are considered 
an absolute essential part of corporate strategy and accordingly investments are being 
made (company interviews and visits to research parks). The enhanced levels of key 
activities are discussed below: 
 
Enhanced R&D Investments  
Changes in patent law under TRIPs obligation, preventing the reverse engineering of 
patented molecules has forced Indian firms to enhance their R&D efforts and 
investments. Our case studies suggest that from about 2 per cent of total sales around 3-4 
years ago, the average R&D expenditures of the leading research based domestic firms 
has gone up to around 5-6 per cent in 2003-2004 (Table 4). Among these companies 
Ranbaxy, Dr. Reddy’s, Cipla, Wockhardt, Torrent, Sun, Lupin and Nicholas Piramal are 
prominent. Dr. Reddy’s R&D expenditure increased from 7 per cent in 2002-03 to 10 per 
cent in 2003-04 and is slated to increase further in future.  
 
Table 4 
R&D Investments in Selected Indian Pharmaceutical firms 
R&D Spend as % of Sales 
Company 
1999-00 2000-01 2001-02 2002-03 2003-04 2004-05* 
Ranbaxy 3.6 4.2 4.0 5.0 - 5.5 6.3 7.0 - 8.0 
Dr. Reddy’s 2.7 3.5 4.0 - 4.5 6.8 9.9 12.9 
Cipla 3.5 3.5 4.0 - 4.5 4.5 - 4.8 4.8 - 5.0 5.0 - 5.5 
NPIL 2.0 2.0 2.0 2.0 4.0 5.0 
Sun 4.0 4.0 4.0 7.0 10.0 10.0 - 12.0 
Lupin 1.7 2.0 2.0 3.0 3.0 - 3.5 8.0 
Dabur - - - - 8.0 - 9.0 8.0 – 9.0 
Cadila Pharma 1.0 - 2.0 1.0 - 2.0 1.0 - 2.0 2.0 2.0 - 3.  3.0 - 4.0 
Sources: Compiled by Chaturvedi from various sources (Company interviews, Annual 
Reports, Journal Articles and Press releases.  * repres nts projected investments. 
 
At the macro-level, the total R&D expenditure, which was only Rs. 3 crores in 1965-66, 
reached an impressive Rs. 140 crores in 1995, a significant year, when the WTO and IPR 
protection came into being. With the increasing realization that copying will no longer be 
permissible after 2005, R&D investments have gained s rious momentum since the late 
1990s (Mashelkar 2001).  
 
Enhanced Patent Filings 
The number of patents filed and granted in a particular sector indicates the level of 
inventive activity and R&D capabilities of a country in that sector. Two Indian entities, 
CSIR (Council of Scientific and Industrial Research) and Ranbaxy, find mention in the 
top ten list of World Intellectual Property Organization (WIPO)’s list of 2002. Patent 
applications by industry during 1995-2000 indicate that pharmaceuticals ranks highest 
with 396 applications). India filed more than 112 ANDAs (abbreviated new drug 
applications) in 2003 and 392 in 2002. India’s share of ANDA filings has been rising 
consistently and was around 23% in 2003 (IPR, various ssues). 
 
Firms have used multiple approaches to create intellec ual property such as filing for 
Indian patents, international patents, ANDAs, and DMFs (drug master files). Firms like 
Dr. Reddy’s and Ranbaxy have made use of first-to-file and Para-IV filings as well. 
However, other firms like Cipla, Cadila, Lupin, Sun a d Zydus have opted for DMFs to 
gain cheaper and faster entry to regulated markets (Table 5). Indian firms accounted for 
over 30% of the DMFs filed in the USA in 2003 (Chaturvedi and Chataway 2006). It 
remained in first position with 126 DMFs in 2003 alone (India Folio 2004). This 
indicates not only the present level of patenting activity in Indian pharma but 
commitment (pipeline) for the future as well.  
 
Table 5 
Patent Filings by Indian Pharmaceutical Majors 







Target Filed Target 
Ranbaxy 489 127 
(92*) 
22 12 15-20 48 (2003) 15-20 
DRL 213 42 (12*) 24 9 15-18 100 (56 in 
2003) 
20 
Cipla NA 15 
(35**) 
15 5 15-20 53 (in 2003) 20 
Sun 132 13(2*) 0 0 8-10 22 8-10 
Lupin 162 13(5*) 0 0 12-16 82 (21 in 2003) 20-25 
Source: Compiled by Chaturvedi from various sources. *represents approved,  ** 
represents to be filed in 2004-2005. 
 
Enhanced Collaborations for Research and Development 
Indian firms have collaborated aggressively with premium technology and research 
institutions in the recent past with the main objectives of integrating new knowledge and 
skills from external sources and for changing their market image (research driven). 
Ranbaxy, Cipla, Lupin, Cadila pharmaceuticals, Dabur, Zydus, Wockhardt, Sun and 
Torrent are all involved in such alliances. These firms have acquired assets and formed 
alliances with the firms based in other countries to expand their international presence on 
one hand and have collaborated with premium technology institutes to strengthen their 
technology base. Acquiring firms with existing innovative product lines or products in 
the advanced stage of development is favored by the leaders. Coordinating and 
redeploying internal and external sources appears to be the key strategy to address the 
rapidly changing technology and business environments.  
 
Case analysis in this paper suggests that the focus f collaborations in 1990s was on 
integrating brands, manufacturing capacities, and marketing and distribution networks. 
Vertical integration achieved new heights during market liberalization in 1990s. 
Ranbaxy, Nicholas Piramal, Sun, Lupin, Cipla all expanded their manufacturing 
operations, marketing and distribution networks, product portfolios and brands through 
backward and forward integration. Ranbaxy bought 30 per cent stake in Vorin 
Laboratories in order to gain control over a key raw material and intermediate supplier 
for its famous product Ciprofloxacin. Sun Pharma utilized acquisitions for its organic and 
inorganic growth. Its acquisition of MJ Pharma and Gujarat Lyka was a part of its multi-
media strategy while integrating TDPL is an entry strategy into specialties areas like 
oncology, gynaecology and pain management. However, with the signing of TRIPs in 
1995 and changes in the patent laws, the focus of collaborations has shifted to research 
and development. The emphasis is on knowledge and technology integration rather than 
the critical mass and economies of scale. Many top Indian firms have pursued 
collaborations with international drug companies to access technology and knowledge 
vigorously in last 5 years or so. For example, Ranbaxy with Eli Lilly and Gist Brocades, 
Dr. Reddy’s with Novartis and Novo Nordisk, Lupin with Merck Generics and Wyeth 
Lederle, Torrent pharmaceuticals with Novo Nordisk of Denmark and Sanofi of France 
and Cadila Pharmaceuticals with M M Schwabe, USA. Nicholas Piramal has acquired 
R&D facilities from international leaders such as Hoechst, Boehringer Mannheim and 
Roche in order to augment its knowledge base. Sun Pharma’s acquisition of USFDA 
approved Caraco Pharma Labs and Knoll’s bulk laboratory was also motivated by the 
firm’s technological strengthening strategy.  
 
Recent trends suggest a change in the mindset of Indian entrepreneurs and change in the 
motives behind strategic alliances pursued by the Indian firms. India firms have 
ambitious plans to launch their own new chemical entiti s (NCEs) and new drugs and 
have charted R&D strategies to build and fuel their drug discovery pipeline albeit with a 
different time-frame (short, medium and long).  
 
5.2 Knowledge and Innovation Management in the Post-TRIPs Regime 
The ‘dynamic capabilities framework’ by Teece et al (1997) directly addresses a firm’s 
ability to strategically integrate, build and reconfigure internal and external competencies 
to address rapidly changing environments. The approach emphasizes firm-specific 
capabilities, assets, paths and strategies. The capabilities here do not represent 
technological capabilities alone but also management capabilities and difficult-to-imitate 
combinations of organizational, functional and technological skills. Elements of this 
approach are evident in the overall corporate strategy of our cases. Various initiatives 
have been taken by firms to enhance and accelerate research and innovation in drug 
development. For example, licensing product patents from patent holders; acquiring their 
own patents through indigenous R&D; and integrating new knowledge and resources 
from external sources. Consortia approaches, involving universities and national 
laboratories within and across boundaries for new drug discovery, are increasingly 
finding favor with technology intensive firms (Sakakibara & Dodgson 2003, Bower and 
Sulej 2005). 
 
Chiesa and Toletti (2004) in their recent study of biotechnology sector highlighted the 
role of strategic alliances in the development of R&D capability, the rate and quality of 
innovation, knowledge transfer; and organisational le rning. Resonating the same Indian 
firms also assert that innovative capacity is a determinant key factor of a firm’s 
competitive standing in global markets and strategic alliances are key to achieve 
knowledge advantages. Within this approach ‘cooperate’ r ther than ‘compete’ is the 
mantra for success. Ranbaxy teaming up with its otherwise local competitor firm Cipla 
for marketing Carvedilo is a case in point. Firms are not opting for aggressive 
competition with domestic firms or with the established international players in the near 
future, though some of the visionary firms in the top league with strong financial muscle 
and better infrastructure may use a combination of co peration and competition. The idea 
is to acquire, assimilate, innovate and then compete (company interview). Strategic 
outsourcing and in-sourcing has assumed an increasingly important role in the operations 
of established as well as emerging pharmaceutical firms in India.  
 
Subcontracting 
Large scale subcontracting of research is a relativly recent phenomenon in the 
pharmaceutical industry. There is an increasing recognition in Indian pharmaceutical 
firms that one company’s peripheral technologies ar on other’s core activities, and that it 
makes sense to source such technologies externally rather than to incur the risks, costs 
and most importantly of all, time-scale associated with the in-house development. Earlier, 
subcontracting in pharmaceuticals was mainly restricted to intermediate or APIs 
suppliers. Now as the firms are moving up the higher value chain and competing to 
launch new drugs, subcontracting for research, clinical trials, custom synthesis, marketing 
and sales support is gaining popularity. Increasingly, superior capabilities are being 
developed by the companies that concentrate on single element of drug development. 
Organisations like Siro-Clinpharm-a group company of Bharat Serums and Vaccines, 
Syngene-a subsidiary of Biocon India, Wellquest-a subsidiary of Nicholas Piramal, 
Aurigene-a sister concern of Dr. Reddy’s and Clingene International-a group company of 
Biocon India are offering contract research services n India. These organisations provide 
research services all along the discovery chain including structure-guided generation of 
hit molecules from novel targets, validated targets, and drug-like molecules besides 
conducting clinical trials. Vimta Labs, Lambda Therapeutic Research, Synchron 
Research Services, ClinInvent Research, iGATE Clinical Research International, 
Genotex International, and ClinTec International are the other major clinical research 
organizations operating in India. Clinical trials are the most expensive and time 
consuming stage of the drug development and innovation process. Our case studies 
indicate that Indian firms possess resources that sould allow the industry to offer high 
end value services at a very competitive cost. Regulatory system at operational level, 
however needs to brace itself to be in sync with the ambitions and strategies of these 
firms.  
 
Western multinationals are vigorously scouting for clinical development services and the 
painstaking chemical synthesis work for early drug development in India. They are also 
shopping for promising new treatments that may emerge from India's own drug discovery 
efforts. Backed by the recent government notification amending Schedule Y, 
multinationals like Pfizer, Eli Lilly, GlaxoSmithKline and Aventis have kick started 
simultaneous and stand-alone clinical trials in various therapeutic segments. Eli Lilly has 
over 17 large and small clinical research projects running in 40 hospitals across India, 
while GSK Plc has started seven simultaneous clinical trials of its vaccines and drugs. 
Global consultancy major McKinsey (2003) estimates hat by 2010, global pharma 
majors would invest $1-1.5 billion in the Indian market. Clinical research constitutes a 
major part of drug innovation process. Policy impact  (the Schedule Y booster shot and 
TRIPs implementation) at operational level (firms) i  clearly visible which heralds 
changes in the innovation models. 
 
Technology Licensing 
Indian firms (Ranbaxy, Cipla, Dr. Reddy’s, Nicholas Piramal) realise that it will be 
difficult for them to commercialise their discoveris on an international basis on their 
own and hence are getting into licensing deals and strategic alliances with international 
companies. The cases under study suggest a change in the traditional technology 
development and commercialization practices (where most of the innovations have 
emerged from in-house R&D efforts) to more open andparticipative approaches. Dr. 
Reddy’s and Ranbaxy have licensed-out their molecules in order to gain advantages 
related to speed to market, early launch and cost savings. Dr. Reddy licensed two of its 
compounds to Novo Nordisk for Phase II clinical trials and further development. Besides 
enabling Dr. Reddy’s to take its molecule to the market faster, the strategy has helped the 
firm to strengthen its learning about discovery, development and commercialisation of 
NCEs. The strategic integrated discovery approach has helped meld talent and skills 
throughout the organization (company interview).  
 
Similarly Ranbaxy licensed-out the development of a unique once a day formulation of 
Ciprofloxacin to Bayer AG- that has been a breakthrough success for the company. Cipla 
has been involved in intensive technology buying and selling worldwide. Cipla has 
licensing agreements with Canadian generics manufacturer Novopharm; with MCPC of 
Saudi Arabia for formulations; with Cipharm in Ivory Coast for formulations; with 
Geneva Pharma in the US, which is now a part of Novartis for generics; and with a host 
of manufacturers of antibiotics, anti-cancer and other life saving drugs in China. Thus a 
mix of licensing in and out is being used by Indian firms to acquire knowledge and 
expertise from external sources. 
 
Thus on one hand Indian firms are providing high value services to multinational giants 
and on the other hand sourcing the missing links of in-house drug innovation from them. 
The combo strategies of exploiting the ‘existing’ and developing ‘new’ capabilities 
makes perfect business sense and is increasingly being practised by the Indian leaders 
(KPMG 2003, Merchant 2004, Company interviews). In this version of advanced catch 
up model, firms (in developing countries) are increasingly able to challenge leading firms 
in developed countries (Hobday 2002). The study of these emerging patterns not only 
indicates deviation from the past practices but also guides current and future processes of 
innovation as imitator firms increasingly reach thefrontier of technology, perform R&D 
and compete in the global market place. 
 
6. Implications for Innovation Theory 
Since the advent of the embryonic model almost a century ago, innovation process has 
gradually and continuously evolved over time in line with technology development and 
environmental change (Park 2006, Nieto 2002, Amidon 1996, Rothwell 1994). Many 
authors like Nelson 1982, Freeman 1997, Rothwell 1992, and Mytelka 2003 in their study 
of innovation systems, have introduced a multitude of factors to account for the enhanced 
complexities and changes in the process over a period of time. A review of Rothwell’s 
five generations models confirms that each generation had a different model and every 
new (generation) model had some new dimensions and perspective added to the previous 
(generation) model. This interpretation demonstrates changes in the driving forces and 
critical factors for success over time and therefore changes in the innovation models. 
Working along the same lines, finding of this research strongly indicates that the relative 
importance of forces (science, technology, policy, market, and economics) driving 
innovation vary considerably during different phases of maturity. It suggests that one or 
several of these forces became in a general way the most dominant corporate strategy 
focus - science in the early 40s; process technology (push) in the 70s; manufacturing in 
the 80s; marketing and distribution in the 90s; andresearch and development from 2000 
onwards. This indicates that the intensities of driving forces are time dependent as are the 
synergies among them. In fact, various metaphors in the study of knowledge-based 
innovation systems can be considered as appreciations of a complex dynamics from 
different perspectives which keep changing with time.  
 
In India, since the 1990s the situation appears to have a broad combination of central 
strategic themes like mergers and acquisitions, technological accumulation, inter-firm 
collaborations, and product and manufacturing integration (Rothwell’s SIN model). The 
situation has been further aggravated by knowledge-base expansion and global strategies 
themes (contract research, contract manufacturing, custom synthesis) coming to the fore. 
Our case studies suggest knowledge and policy (which are now more global) as the major 
driving forces of the present times. Synergy between these two forces exerts a strong 
influence on firm innovation approaches which in turn has implications for theory of 
innovation.     
 
Co-evolution of the technology (genomics, proteomics, new technology platforms) and 
policy developments in the 20th century clearly demonstrates changes in the innovation 
and wealth creation approaches (strategies) at firm level. Rapidly changing technology 
and policy environments have transformed the majority of wealth-creating work from 
“physically-based” (labour and capital intensive) to "knowledge-based”. As our case 
studies demonstrate the major comparative advantage that a company enjoys in the 
present context, hinges on its process of innovation that essentially involves combining 
market and technology know-how with the creative prowess of new knowledge. 
Knowledge is at the heart of corporate strategy and in ovation model. Virtually all other 
resources depend upon some degree of knowledge exploitation for their value. Firms are 
exploiting knowledge in order to build innovative capabilities and competencies and to 
exploit new markets (geographical as well as technical) and opportunities. Modern 
literature on innovation management further confirms knowledge as the most critical 
resource and asserts that in the new perspective, knowledge management ought to be 
considered as a strategic necessity for firms (Park and Kim 2006, Jones 2002, Pavitt 
2002, Malerba and Orsenigo 2001). These knowledge-led-innovations are a strong 
invitation to redefine the basic innovation model and to further analyze the contractual 




6.1 Changing Innovation Dynamics 
Innovation theories and models have since evolved from simple linear sequential models 
to what Rothwell (1992) refers to as third, fourth and finally fifth generation (System 
Integration Networking) model. Rothwell’s fourth and fifth generation innovation models 
are based on research observations during 1980s and 1990s, highlighting an increase in 
corporate alliances, partnerships, R&D collaborations and joint ventures. These models 
placed additional emphasis on the high degree of crss-functional integration within 
firms, as well as external integration of capabilities from other firms, suppliers, 
customers, government and academia. The emphasis throughout is on internal 
integration.  
 
Until the mid 1990s, the fourth generation model represented a close approximation to 
actual global best practice. The advent of biotechnologies, computing technologies, 
multidisciplinary R&D and new policies, however, adde  many more dimensions to this 
model. In response to the changing environment and context, a new fifth generation 
model emerged placing increased emphasis on the strategic integration for co-
development of new products, collaborative research, co-marketing, corporate flexibility 
and focus on standards services and other non-priced factors.  Thus despite enhanced 
merger and acquisition activity, innovation in the pharmaceutical industry has become 
increasingly diffuse across firms in the recent past.  
 
The global literature on pharmaceutical research also suggests that the corporate structure 
of the industry is changing rapidly as new companies proliferate and large companies 
consolidate to deal with the growing cost and complexity of new drug development. 
Simultaneously, and partly as a result of these changes, new centres of excellence are 
identified around the globe. India, Brazil, China, and Mexico are beginning to appear on 
the global pharmaceutical map. This future map of gl bal pharmaceutical R&D and 
innovation appears to be significantly more fragmented than the present one. India is 
becoming an integral part of the global pharma value chain, as large global pharma 
companies continue to increase their sourcing of APIs, offshoring of clinical development 
and partnering with domestic companies for new product evelopment and marketing in 
India. Today new business led-R&D models are more obvious than was previously 
predicted.  
 
Focus on the business, science and economics of NCEdiscovery wherein clinical 
research in India promises major contribution exerts a strong influence on firm level 
innovation approaches at national as well as at international level. The R&D function in 
business firms world over has shifted focus to the strategic integration of R&D effort 
with overall business goal. These shifts reflect the increasing complexity and maturity in 
which companies are tackling the management of their knowledge/technology, products 
and markets. Knowledge integration from external sources on one hand and 
fragmentation of the drug innovation process for exploiting time, cost an market 
advantages on the other, represent extreme complexity of the contemporary innovation 
model. Striking the right balance between ‘integration’ and ‘fragmentation’ and 
managing the tension between the two is a crucial task faced by firms across the globe. 
Outsourcing, co-development deals, and in and out-licensing are common features in 
pharmaceuticals. Discovery alliances between Indian and international companies like 
AstraZeneca/Torrent, Lilly/Jubilant, GSK/Wyeth and clinical trials alliances from 
Avalon, Triesta, Merck KGaA and MSD Pharmaceuticals bring testimony to the 
complexities and changes in the drug innovation process/model.  
 
6.2 ‘Innovation’ in Innovation Models 
The discussion in this paper has provided enough evidence to corroborate that the debate 
on innovation has shifted focus from individual outputs to the ‘mechanisms’ for 
producing these outputs. During this transition the realisation has grown that knowledge 
creation and its commercialization requires participation of many organisations and 
individuals. Weakness of one organization can be ovrcome by partnering with the 
leaders (organizations) or experts in that area.  
 
The resulting system constitutes a dense and complex network of interconnected parts 
which in literature signifies an intensification oflinkages across the innovation system. 
The major actors in this system - the private sector, the public sector, government 
departments and ministries, universities and technology institutes-relate to each other in 
complex ways. In the Indian pharmaceutical sector the more innovative elements of the 
national innovation system are largely centered in the private firms. These firms are 
acquiring and integrating knowledge, information, technology, brands and markets from 
external sources in addition to enhancing their in-house efforts.  
The sole focus on strategic integration and in-house R&D of the 1990s is slowly but 
surely changing to contract research and outsourcing. Most of the firms interviewed for 
this research are of the view that integrating every task within the firm does not make 
much economical sense or gain even time advantages. The idea of developing core 
competencies in few and capacities to absorb the rest from outside is increasingly being 
practiced in most of the firms. Rothwell’s 5th generation models emphasized the need for 
internalisation to a very high degree. The current trends, however, indicate a combination 
of integration and fragmentation. The reasons may var across the countries depending 
upon their level of maturity and size but in general pharmaceutical firms are adopting the 
decoupling model. In the developed part of the world low R&D productivity, high R&D 
costs and sustainability of such high expenditures for long term are cited as the main 
reasons whereas in India lack of financial, infrastructural and technological resources for 
taking the new molecules to the market place is the main reason.  
 
Although Rothwell’s 5th generation model is quite adv nced and explains iteration 
within an organisation, it falls short in explaining external networks. Thus in the current 
form Rothwell’s model is not appropriate for dealing with new forms of innovation and 
requires updating. New models of successful participation between large integrated 
players and niche players is strongly emerging both at national and international level: 
niche players that optimize a part of drug discovery p ocess to provide services to 
integrated companies; and large players that control the overall development but source 
best services available both internally and externally. Emerging trends indicate that 
although some large firms may asses the external options and continue to integrate 
vertically, a majority of firms will choose to narrow their activities to one niche or at the 
most  a few and outsource the rest. The firm level analysis observed contracting rather 
than integrating to be the optimal strategy.  
 
7. Conclusion 
Collective analysis of selected cases in this paper implies that Indian firms are adapting to 
the changing environments by making midway strategic corrections and are continuously 
integrating new parallel streams in the mainstream of corporate strategy. R&D is 
recognized as the ‘survival kit’ in the post-TRIPs scenario and building the science base 
for innovations is deemed necessary for long-term gowth by Indian leaders. Most firms 
have reconfigured their research on short, medium and long term bases. Firms have 
devised strategies to maintain a steady cash flow tapping the large US generics market 
and by leveraging their manufacturing and clinical research strengths/services in the short 
term. In the medium term, they intend to move up the value chain through NDDS which 
can be patented and finally in the long term launch their own molecules. The paper 
observed that Indian firms are investing in R&D notonly for new drug discovery but for 
developing capabilities to assimilate and exploit knowledge available externally; and for 
positioning themselves as a partner of choice for technology savvy national and 
multinational firms. The indigenous capability development is viewed as a powerful 
strategic tool to exchange and acquire new and emerging technologies from external 
sources.   
 
On the innovation process front, rapid changes in technologies and external environment 
beyond the control of a firm are revolutionizing the drug discovery process and approach 
to innovation. Large firms are strategizing to cater to advanced, regulated and diversified 
markets, but they are not trying to create in-house expertise for all. Instead they are 
spreading their research and knowledge networks. As the pharmaceutical innovation 
model evolves further and external providers develop superior skills and knowledge, the 
integrated companies are being transformed through a complex web of partnerships and 
alliances. The fifth generation integration model appears to be evolving into a new 
decoupling model. The findings of this analysis suggest that in the new policy and 
knowledge intensive environment, one company can ide t fy a new compound, another 
can process and develop it, a third can carry it through clinical development and still 
fourth can launch it.  
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